Sickle cell disease (SCD) is an autosomal recessive disorder characterized by chronic haemolytic anaemia and painful vaso-occlusive crises. SCD is common in sub-Saharan Africa, with a birth prevalence that in some areas reaches 2% [1], and where it is therefore a true issue of public health importance. Without early diagnosis and appropriate care many children born with SCD do not survive beyond their fifth birthday [1, 2].

SCD patients also experience increased susceptibility to severe infections, including malaria [3, 4]. This is particularly important because the geographic distribution of SCD parallels closely that of malaria, both disorders being frequent in the entire tropical belt of Africa, including Tanzania [5, 6]. This parallel epidemiology is not a coincidence: rather, there is evidence that heterozygotes for the sickle gene (Hb genotype AS) are relatively protected against death due to malaria, probably through accelerated clearance by macrophages of Plasmodium falciparum-infected erythrocytes [7]. On the other hand, homozygous (Hb SS) SCD patients are at increased risk of dying from malaria [3, 4, 7].

Splenic dysfunction may be responsible for increased susceptibility of SCD patients to malaria as well as to other infections [8, 9], as removal of abnormal erythrocytes and of intra-erythrocytic inclusions, including parasites, is one of the main functions of the spleen [10, 11]. Therefore, persons who are either splenectomized or who have impaired splenic function have increased susceptibility to malaria [11, 12]. Immunity against malaria is complex, but in malaria-endemic areas some degree of immunity develops regularly. This may be weakened when recurrent exposure ceases, for example in a person who has moved to a malaria-free area [13].

In view of the higher malaria mortality rate in SCD patients, although it is questionable whether anti-malarial prophylaxis reduces the frequency of vaso-occlusive crises [14], this prophylaxis is recommended [15], but it is far from universally practiced in sub-Saharan countries [1, 5]. This is true in Tanzania where anti-malarial chemoprophylaxis for SCD patient is an established policy that, however, is far from being regularly implemented.

This is a report of a patient with SCD who was asplenic, who had lived for several years in malaria-free environment and who, upon return to Tanzania, did not initially receive anti-malarial prophylaxis and suffered recurrently from malaria.

Case presentation

A 17 year-old Tanzanian male with known SCD came in May 2018 to the Sickle Cell Clinic at the Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania with a complaint of loss of appetite and nausea. The day before the patient had been discharged from a local hospital in Dar-es-Salaam where, having been admitted 5 days previously because of fever, nausea, loss of appetite, generalized body pain and weakness. Plasmodium falciparum malaria infection was diagnosed upon microscopic examination of blood slides. The patient was treated with artesunate injection followed by quinine tablets. A similar episode, with confirmed P. falciparum infection, had occurred some weeks earlier, when the patient had been treated with artemether-lumefantrine tablets.

The medical history showed that the patient had been diagnosed with SCD at the age of 2 years. At the age of 5 years when living in the USA, the patient was started on hydroxyurea. In 2007, he returned to Tanzania where, in 2008, he had an episode of malaria. In 2010, the patient moved to France where further investigations revealed that his SCD was sickle beta thalassaemia, and that he was also homozygous for alpha-thalassaemia. The beta thalassaemia mutation was identified as IVS1nt5G > C. Deficiencies of coagulation factors VII and X were also detected. His steady-state Hb level was 10–11 g/dL; however, he required blood transfusion on 9 occasions because of recurrent exacerbations of anaemia, attributed to hypersplenism and recurrent splenic sequestration. Therefore in 2014 he had a laparoscopic splenectomy. The spleen weighed 428 g and histology showed marked congestion without haemosiderosis or other abnormalities.

In 2016, the patient returned to Tanzania where he now attends secondary school. In 2017 the patient was feeling so well that he stopped taking hydroxyurea, his steady-state haemoglobin being 9–10 g/dL, and his only medication was folic acid (5 mg/day). However, recently he has had several bone pain crises.

On admission to MNH in May 2018 clinical examination did not reveal any specific findings. There was no severe pain and no evidence of infection. The patient’s Hb was 7.3 g/dL and a malaria test was negative. The patient continued on folic acid, hydroxyurea (500 mg/day) was re-introduced, and anti-malarial prophylaxis with proguanil (100 mg/day) was started. On monthly follow-up visits from June 2018 to September 2019 the patient has been generally well, except for occasional pain that responded to paracetamol, diclofenac or ibuprophen. Laboratory findings (Table 1) were stable.

Table 1 Laboratory findings obtained at hospital admission and outpatient follow-up visits

A high performance liquid chromatography haemoglobin analysis confirmed in this patient the diagnosis of sickle beta thalassaemia (Table 2). The mother is an A/S heterozygote and the father is a beta-thalassaemia heterozygote. Surprisingly, the patient’s sister, who reports having been generally well, was also found to have sickle beta thalassaemia.

Table 2 Blood profiles of patient and his family members


Malaria infection may be fatal in any person: however, the risk of fatality is influenced by several genetic and acquired factors. Among the former, SCD is one of the foremost: it increases greatly the mortality from malaria infection; probably in large part because the P. falciparum-induced destruction of both parasitized and non-parasitized erythrocytes will precipitate a severe exacerbation of the already existing chronic anaemia [16, 17]. This is in striking contrast to the well known significant protection enjoyed by haemoglobin S heterozygotes (sickle cell trait) against P. falciparum malaria [7], and the triumph of good over evil: protection by the sickle gene against malaria [18]. In SCD malaria can also trigger painful vaso-occlusive crisis in SCD patients and it is among the leading causes of hospital admissions and mortality in endemic countries [3, 13].

As for acquired factors, partial immunity against malaria is usually acquired during the first 5 years of life, is dependent on the intensity of transmission and, therefore, on exposure frequency [19], and it tends to wane off with time if re-exposure does not occur [19, 20]. A previous study has found that immigrants of African origin who had lived in Sweden (a malaria-free country) for 15 years or more, once they returned to Africa had a risk of malaria infection and of severe malaria similar to that of non-African travellers [20]. In the defense against malaria a significant role is played by the spleen because, by virtue of its unique anatomy, it can retain parasitized erythrocytes (as well as non-parasitized, but otherwise abnormal erythrocytes); indeed, impaired splenic function reduces the clearance rate of malaria parasites from the circulation [8, 10, 11]. In SCD by early adulthood auto-splenectomy or functional asplenia is the rule rather than the exception: but, compared to homozygous sickle cell anaemia (SS), in sickle beta-thalassaemia the spleen is much more likely to persist and to remain enlarged even in adults. This may be associated with pooling of blood in the spleen that intermittently becomes greater (splenic sequestration) [21], whereby indications for splenectomy are more often compelling in sickle beta-thalassaemia compared to homozygous sickle cell anaemia.

In this patient each one of these factors seems to have conspired with the others: (i) The patient had sickle beta thalassemia, a well known form of SCD; (ii) he was asplenic; and (iii) after being born and having lived in Tanzania for the first 4 years of his life, he lived for a total of 8 years in malaria-free countries (USA and France), whereby whatever immunity he had previously developed may have faded. He had at least two documented episodes of malaria infection prior to his splenectomy, and at least two after splenectomy. In this patient, therefore, the spleen was removed for good clinical reasons, and the procedure was recommended only after a balanced judgment of pros and cons. One goal was to reduce substantially the rate of blood transfusion, and this was achieved. As for the implications of being asplenic, it must be accepted that living in a malaria-endemic region is an added risk.

Malaria episodes in this patient have been treated promptly: fortunately, because in a splenectomized SCD patient it might rapidly become life-threatening, a decision was made to institute anti-malarial chemoprophylaxis [15]. Officially recommended regimens in Tanzania include weekly mefloquine, daily atovaquone/proguanil, daily doxycycline, or weekly artemisinin-based combination therapy. None of these options is without side effects [22], in addition, the patient could not afford any of them. Hence, a widely used proguanil monotherapy drug was prescribed [23, 24]. Since Dar-es-Salaam is regarded as a low malaria transmission area, prophylaxis cannot be automatically credited with having prevented further episodes of malaria infection, but in the 18 months since starting proguanil the patient has had no malaria recurrence, no fever and no hospital admission. Since his last hospitalization in May 2018, his Hb level has risen significantly, which may be attributed to the combined effects of not having malaria infection and having resumed hydroxyurea therapy. Nonetheless, this case report illustrates what can happen (and probably often does happen) when anti-malarial chemoprophylaxis is not provided.


This patient was a living reminder that if SCD cannot be cured, then at least patients with SCD should be protected from falciparum malaria, an exogenous extra threat that is preventable.